Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $56.33.

Several research analysts have commented on the company. Royal Bank of Canada raised their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Scotiabank upped their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th.

Agios Pharmaceuticals Trading Up 2.2 %

Shares of AGIO stock opened at $35.90 on Friday. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of 3.16 and a beta of 0.87. The firm has a 50-day moving average price of $46.77 and a 200 day moving average price of $45.50. Agios Pharmaceuticals has a twelve month low of $20.96 and a twelve month high of $62.58.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in AGIO. Nordea Investment Management AB raised its stake in Agios Pharmaceuticals by 3.6% during the 4th quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company’s stock valued at $7,191,000 after purchasing an additional 7,593 shares during the period. Exome Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $2,941,000. Franklin Resources Inc. purchased a new position in Agios Pharmaceuticals during the 3rd quarter valued at about $1,499,000. Geode Capital Management LLC grew its stake in Agios Pharmaceuticals by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. increased its holdings in shares of Agios Pharmaceuticals by 19.7% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock valued at $46,392,000 after purchasing an additional 172,180 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.